Clinical Trials on Nephrotic Syndrome in New Zealand

Total 4154 results

Fisher and Paykel Healthcare

Completed

The Evaluation of a Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ

Obstructive Sleep Apnea

New Zealand
Fisher and Paykel Healthcare

Completed

Evaluation of a Full Face Mask and Headgear for the Treatment of Obstructive Sleep Apnea

Obstructive Sleep Apnea

New Zealand
University of Michigan

Completed

Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease

Focal Segmental Glomerulosclerosis | Minimal Change Disease | FSGS | MCD

United States
Australian and New Zealand Intensive Care Research...
Melbourne Health; The Alfred; Barwon Health; Wellington Hospital; Monash Health; Austin... and other collaborators

Completed

The Vitamin C, Hydrocortisone and Thiamine in Patients With Septic Shock Trial (VITAMINS)

Sepsis | Shock, Septic | Critically Ill | Vasoplegic Syndrome

Australia, New Zealand, Brazil
Otsuka Australia Pharmaceutical Pty Ltd

Recruiting

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia (PREFER-HMA)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Myelomonocytic, Chronic | Patient Preference

New Zealand, Australia
Genzyme, a Sanofi Company

Completed

ATHENA: Natural History of Disease Study in Alport Syndrome Patients (RG012-01)

Alport Syndrome Patients With eGFR Between 45-90 ml/Min/1.73 m2

France, Germany, Australia, United States, United Kingdom, Canada
Fisher and Paykel Healthcare

Terminated

Nasal High Flow Therapy for the Treatment of Respiratory Insufficiencies During Sleep

Sleep Disordered Breathing | Congestive Heart Failure

New Zealand
Bellus Health Inc
FDA Office of Orphan Products Development

Completed

Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis

Gastrointestinal Diseases | Kidney Diseases | Rheumatoid Arthritis | Nephrotic Syndrome | Secondary (AA) Amyloidosis | Familial Mediterranean Syndrome

United States, Israel, Finland, France, Italy, Lithuania, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom
Fisher and Paykel Healthcare

Completed

F&P Toffee Full Face Mask Clinical Trial, NZ, 2020

Obstructive Sleep Apnea | Positive Airway Pressure Therapy

New Zealand
Ionis Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Effectiveness and Safety of IONIS-FB-LRx, an Antisense Inhibitor of Complement Factor B, in Adult Participants With Primary IgA Nephropathy

Primary IgA Nephropathy

Canada, Australia, New Zealand, Singapore
ImmusanT, Inc.

Completed

Safety and Tolerability of Nexvax2 in Subjects With Celiac Disease

Celiac Disease

New Zealand, Australia
Fisher and Paykel Healthcare

Completed

The Evaluation of an Interface for the Treatment of Obstructive Sleep Apnea (OSA)

Obstructive Sleep Apnea | Sleep Disordered Breathing

New Zealand
Goldfinch Bio, Inc.

Terminated

A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)

Diabetic Nephropathies | Glomerulosclerosis, Focal Segmental | Minimal Change Disease

United States
James Cook University, Queensland, Australia
National Health and Medical Research Council, Australia; The Prince Charles... and other collaborators

Completed

Hookworm Therapy for Coeliac Disease (NainCeD-3)

Celiac Disease

Australia, New Zealand
Hvidovre University Hospital
Physical Medicine and Rehabilitation Research - Copenhagen (PMR-C).; School... and other collaborators

Unknown

Muscle Function, Central Nervous System Sensitization, and Pain Profiling in Patients With Subacromial Pain (SAP-CNSS).

Subacromial Impingement Syndrome | Central Nervous System Sensitization

Denmark
Baxalta now part of Shire

Terminated

Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis

Systemic Lupus Erythematosus

Australia, United States, New Zealand, Mexico, Canada
Yale University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Enrolling by invitation

Biorepository to Support Research in Kidney Diseases

Kidney Diseases | Acute Kidney Injury | Acute Interstitial Nephritis

United States
Fisher and Paykel Healthcare

Completed

The Evaluation of an Alternative Sizing Model in Comparison of a Conventional Sizing Model for Full Face Masks in the Treatment of OSA in Terms of Performance and Comfort

Obstructive Sleep Apnea | Sleep Disordered Breathing

New Zealand
National Cancer Institute (NCI)

Completed

Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases

Primary Myelofibrosis | Chronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndrome | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Recurrent Disease | Recurrent Adult Acute Lymphoblastic Leukemia | Secondary Myelodysplastic Syndrome | de Novo Myelodysplastic... and other conditions

United States, Canada, New Zealand
NeuroActiva, Inc.
Biomed Industries, Inc.

Unknown

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19 (OPV-NA831)

Covid19 | SARS-CoV-2 | SARS-CoV Infection | SARS (Severe Acute Respiratory Syndrome)

New Zealand, United States
Rigel Pharmaceuticals

Recruiting

Study of R289 in Participants With Lower-risk Myelodysplastic Syndromes (LR MDS)

Low Risk Myelodysplastic Syndromes

United States
Travere Therapeutics, Inc.

Recruiting

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases (EPPIK)

Focal Segmental Glomerulosclerosis | Immunoglobulin A Nephropathy | Minimal Change Disease | Alport Syndrome | IgA Vasculitis

United States, Italy, Netherlands, Poland, Spain, United Kingdom, Germany, Sweden
Omeros Corporation

Recruiting

Safety and Efficacy Study of OMS906 in Patients With C3G and ICGN

C3 Glomerulopathy | Idiopathic Immune Complex-Mediated Glomerulonephritis

Lithuania, New Zealand, Poland, Tunisia, Turkey, United Kingdom
Alexion
Achillion, a wholly owned subsidiary of Alexion

Completed

A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria

New Zealand, Korea, Republic of, Italy
Rockefeller University

Completed

Immunotherapy of the Paraneoplastic Syndromes

Paraneoplastic Syndromes

United States
University of British Columbia

Completed

Predicting Complications in Women With Toxaemia

Toxemia

United Kingdom, Canada, New Zealand
Apellis Pharmaceuticals, Inc.

Completed

Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects. (PADDOCK)

Paroxysmal Nocturnal Hemoglobinuria

Hong Kong, Thailand, New Zealand, Malaysia
Onconova Therapeutics, Inc.

Completed

Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs

Myelodysplastic Syndromes

United States, France, Germany
Weill Medical College of Cornell University
Novartis Pharmaceuticals

Completed

MRI Screening for Patients With Myelodysplastic Syndrome (MDS), Who Have Received Multiple Red Blood Cell Transfusions (T2*MRI)

Myelodysplastic Syndrome (MDS)

United States
Keros Therapeutics, Inc.

Recruiting

A Study of KER-050 to Treat Anemia Due to Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Cytopenia

Australia, Spain, United States, Israel, France, Germany, New Zealand, Czechia
AbbVie
Celgene; Genentech, Inc.

Completed

A Study Evaluating Venetoclax Alone and in Combination With Azacitidine in Participants With Relapsed/Refractory Myelodysplastic Syndromes (MDS)

Myelodysplastic Syndromes (MDS)

United States, Australia, Germany
Aalborg University
Naestved Hospital

Completed

Catastrophizing and Virtual Reality's Impact on Pain in Patients With Fibromyalgia

Pain | Fibromyalgia

Denmark
Rutgers, The State University of New Jersey
Arthritis Foundation

Completed

HRV Biofeedback in Fibromyalgia

Fibromyalgia Syndrome

United States
Hospital for Special Surgery, New York

Recruiting

Forward Looking InfraRed Imaging and Severity Score in Complex Regional Pain Syndrome (FLIR)

CRPS (Complex Regional Pain Syndromes)

United States
Rockefeller University

Completed

The Study of Immune Cell (T Cell) Activity in Patients With Paraneoplastic Neurologic Syndromes

Paraneoplastic Syndromes

United States
Sumitomo Pharma America, Inc.

Terminated

A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS

Anemia in Myelodysplastic Syndromes

United States
Dartmouth-Hitchcock Medical Center
Dartmouth College

Recruiting

NIRST and ICG-based Perfusion Imaging in Acute Compartment Syndrome

Compartment Syndromes | Compartment Syndrome of Forearm | Compartment Syndrome of Lower Leg

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Decitabine and Tretinoin in Treating Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center; Columbia University; Karyopharm Therapeutics Inc

Completed

Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States
Columbia University
Celgene Corporation

Active, not recruiting

Revlimid in Transfusion Dependent Patients

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University
Celgene

Terminated

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University
CTI BioPharma

Completed

Study of Clinical Efficacy and Safety of Tosedostat in MDS (IST-CTI-MDS)

Myelodysplastic Syndrome

United States
Onconova Therapeutics, Inc.

Withdrawn

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndrome

United States
CSL Limited

Completed

Safety Study of Subcutaneous Ig NextGen 16% in Patients With Primary Immunodeficiency

Primary Immune Deficiency

Australia, New Zealand
Weill Medical College of Cornell University
Sunesis Pharmaceuticals

Completed

Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy

Myelodysplastic Syndrome

United States
Weill Medical College of Cornell University

Completed

Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

Myelodysplastic Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Safety and Efficacy of the Combination of the Antibody Pembrolizumab and Entinostat in Patients With Myelodysplastic Syndrome Who Are Not Responding to Hypomethylating Agents

Myelodysplastic Syndrome

United States
ViiV Healthcare

Completed

Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants

HIV Infections

United States, New Zealand
Intellia Therapeutics

Enrolling by invitation

Long-Term Follow-Up (LTFU) of Subjects Treated With NTLA 2002

Hereditary Angioedema

France, New Zealand, United Kingdom, Netherlands

Clinical Trials on Nephrotic Syndrome in New Zealand

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Moldova

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations